evidence: The mRNA-LNP COVID-19 vaccines, based on early analysis of the clinical trial data, were deemed safe and effective across demographics (45, 46). However, recent peer-reviewed research studies, a wide variety of continuously increasing case reports, and publicly available adverse events databases cast doubts on the safety and effectiveness of these products. [...] Figure 1 COVID-19 mRNA vaccines are associated with higher incidence of adverse events compared to other vaccines. (A). Data derived from CDC VAERS and National Vaccine Injury Compensation Program (NVICP) were depicted as Lg (events/million doses) in the bar chart. The data for COVID-19 mRNA vaccine and other vaccines were from December 2020 to September 2023 and January 2006 to December 2021, respectively. The fold change was calculated as the Lg (events/million doses) ratio of COVID-19 mRNA vaccine to other vaccines or influenza vaccines.(B). Adverse events of concern associated with COVID-19 mRNA vaccines. Data derived from CDC VAERS were analyzed, adverse events of concern (including AESI, adverse events of special interest, defined by CDC) were displayed as symptoms and their # of events, gender proportion and onset interval of each symptom.